Metastatic Bone Pain Pipeline: 10+ Trailblazing Companies Pioneering Next-Gen Therapies | DelveInsight

The metastatic bone pain market is evolving rapidly, powered by cutting-edge research and novel therapies from leading players like Qilu Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, and Progenics Pharmaceuticals. These innovators are redefining treatment paradigms and offering fresh hope to patients worldwide.

DelveInsight's "Metastatic Bone Pain Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Metastatic Bone Pain market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Metastatic Bone Pain drugs, the Metastatic Bone Pain pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Metastatic Bone Pain Pipeline Report
• DelveInsight's metastatic bone pain pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline drugs for Metastatic Bone Pain treatment.
• The leading metastatic bone pain companies include Qilu Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Progenics Pharmaceuticals, QSAM Biosciences, Yong Shun Technology Development, Q.Biomed, Shanghai JMT-Bio, and others are evaluating their lead assets to improve the Metastatic Bone Pain treatment landscape.
• Key metastatic bone pain pipeline therapies in various stages of development include SGT-201, Cabozantinib, KB-105, Samarium-153 DOTMP, and others.
• In March 2025, the FDA approved Fresenius Kabi Biopharma's denosumab biosimilars, Conexxence and Bomyntra (denosumab-bnht), for all indications of the reference products Prolia and Xgeva, expanding access to more affordable treatments for osteoporosis, bone metastases, and other bone-related conditions.
• In March 2025, the FDA approved STOBOCLO (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, denosumab-bmwo), biosimilars referencing Prolia (denosumab) and Xgeva (denosumab), for protecting bone health in cancer patients undergoing treatment. Xgeva is also approved for treating giant cell tumors of the bone that cannot be surgically removed and hypercalcemia of malignancy that worsens after bisphosphate treatment, as stated by the National Cancer Institute.
• In March 2025, the FDA approved Fresenius Kabi Biopharma's denosumab biosimilars, Conexxence and BOMYNTRA (denosumab-bnht), for all indications of the reference products Prolia and Xgeva, expanding access to more affordable treatments for osteoporosis, bone metastases, and other bone-related conditions.
• In March 2025, Laekna (2105.HK) announced that the FDA has approved the IND for LAE120, an internally discovered USP1 inhibitor, for the treatment of advanced solid tumors.
• In December 2024, a study by Hong Kong Baptist University and Shanghai Sixth People's Hospital found that an aptamer developed by HKBU can treat X-linked hypophosphatemia (XLH), a rare bone disease. The aptamer, initially for osteogenesis imperfecta, has received Orphan Drug and Pediatric Rare Disease Designations from the FDA.
• In December 2024, Halozyme Therapeutics announced FDA approval for OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) by Bristol Myers Squibb. This co-formulation, using Halozyme's ENHANZE® technology, is the first subcutaneously administered PD-1 inhibitor and is approved for various adult solid tumor indications, both as monotherapy and in combination therapies.

Request a sample and discover the recent breakthroughs happening in the metastatic bone pain pipeline landscape @ https://www.delveinsight.com/report-store/metastatic-bone-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metastatic Bone Pain Overview
Bone metastasis occurs when cancer cells spread from their original site to the bones. The most common symptoms include bone pain, fractures, spinal cord compression, and elevated calcium levels in the blood. Typically, bone pain is the earliest sign. These metastases can weaken bones, increasing the risk of breaks, and may also lead to hypercalcemia due to calcium leaking into the bloodstream. Bone metastases often indicate advanced-stage cancer and are most frequently seen in breast and prostate cancers. Diagnosis may involve imaging techniques such as bone scans, X-rays, CT, PET, or MRI, depending on the clinical context.

Find out more about metastatic bone pain medication @ https://www.delveinsight.com/report-store/metastatic-bone-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metastatic Bone Pain Treatment Analysis: Drug Profile
QL1206: Qilu Pharmaceutical Co., Ltd.
QL1206 is a biosimilar of denosumab, a humanized monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), thereby blocking the formation and function of osteoclasts responsible for bone resorption. It is being developed for conditions such as osteoporosis, bone metastases, treatment-related bone loss, and giant cell tumor of bone. The drug is currently in Phase III clinical development for treating bone metastases.

AL2846: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
AL2846 is a multi-target tyrosine kinase inhibitor with strong selectivity for c-MET. Its anti-tumor activity is primarily driven by the inhibition of tumor angiogenesis, cell migration, and key oncogenic signaling pathways via c-MET suppression. The drug is currently in Phase II trials for the treatment of bone metastatic non-small cell lung cancer.

Key Metastatic Bone Pain Therapies and Companies
• QL1206: Qilu Pharmaceutical Co., Ltd.
• AL2846: Chia Tai Tianqing Pharmaceutical Group Co., Ltd
• Cabozantinib:. Exelixis
• Samarium-153 DOTMP: QSAM Biosciences

Learn more about the novel and emerging metastatic bone pain pipeline therapies @ https://www.delveinsight.com/report-store/metastatic-bone-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metastatic Bone Pain Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Intramuscular
• Subcutaneous

By Molecule Type
• Peptides
• Polymer
• Small molecule
• Monoclonal antibody

Scope of the Metastatic Bone Pain Pipeline Report
• Coverage: Global
• Key Metastatic Bone Pain Companies: Qilu Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Progenics Pharmaceuticals, QSAM Biosciences, Yong Shun Technology Development, Q.Biomed, Shanghai JMT-Bio, and others.
• Key Metastatic Bone Pain Pipeline Therapies: SGT-201, Cabozantinib, KB-105, Samarium-153 DOTMP, and others.

Dive deep into rich insights for drugs used for metastatic bone pain treatment; visit @ https://www.delveinsight.com/report-store/metastatic-bone-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Metastatic Bone Pain Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Metastatic Bone Pain Pipeline Therapeutics
6. Metastatic Bone Pain Pipeline: Late-Stage Products (Phase III)
7. Metastatic Bone Pain Pipeline: Late-Stage Products (Phase III)
8. Metastatic Bone Pain Pipeline: Mid-Stage Products (Phase II)
9. Metastatic Bone Pain Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.